Genelux Corp 8-K Filing

Ticker: GNLX · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1231457

Genelux Corp 8-K Filing Summary
FieldDetail
CompanyGenelux Corp (GNLX)
Form Type8-K
Filed DateJun 5, 2024
Pages3
Reading Time4 min
Key Dollar Amounts$0.001, $5.25, $4.00, $2.35 m, $5
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Genelux Corp (ticker: GNLX) to the SEC on Jun 5, 2024.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (ch registered Common stock, par value $0.001 per share GNLX The Nasdaq Stock Mar); $5.25 ("Warrants"), with an exercise price of $5.25 per share, at a combined offering price); $4.00 (share, at a combined offering price of $4.00 per share and accompanying Warrant, pur); $2.35 m (erallotment Exercise were approximately $2.35 million, after deducting the underwriting); $5 (an initial exercise price per share of $5.25, subject to certain adjustments as p).

How long is this filing?

Genelux Corp's 8-K filing is 3 pages with approximately 963 words. Estimated reading time is 4 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 963 words · 4 min read · ~3 pages · Grade level 10.7 · Accepted 2024-06-04 21:58:13

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share GNLX The Nasdaq Stock Mar
  • $5.25 — "Warrants"), with an exercise price of $5.25 per share, at a combined offering price
  • $4.00 — share, at a combined offering price of $4.00 per share and accompanying Warrant, pur
  • $2.35 m — erallotment Exercise were approximately $2.35 million, after deducting the underwriting
  • $5 — an initial exercise price per share of $5.25, subject to certain adjustments as p

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Genelux Corporation Date: June 4, 2024 By: /s/ Thomas Zindrick, J.D. Thomas Zindrick, J.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.